SCHEMBL3527489

SCHEMBL3527489

Cc1nc(-c2ccc(C(F)(F)F)nc2)sc1C(OCC(F)(F)F)c1ccc(-c2noc(=O)[nH]2)cc1

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BPGM P07738 1/20 0.38
ALDH1A1 P00352 1/20 0.37
TRPM8 Q7Z2W7 2/20 0.36
PLA2G2A P14555 10/20 0.36
PLA2G10 O15496 3/20 0.36
PLA2G1B P04054 3/20 0.36
PLA2G5 P39877 3/20 0.36
MDM2 Q00987 1/20 0.33
CASP3 P42574 1/20 0.33
RARB P10826 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525623 0.94 ALDH1A1 (0.37) BPGMALDH1A1TRPM8PLA2G2APLA2G10
SCHEMBL3529025 0.90 PTGES (0.33) BPGMTRPM8MDM2
SCHEMBL3530757 0.89 CASP3 (0.35) BPGMMDM2CASP3
SCHEMBL3529145 0.87 DGAT1 (0.35) BPGMTRPM8MDM2
SCHEMBL3530947 0.85 MDM2 (0.34) BPGMALDH1A1TRPM8MDM2CASP3
SCHEMBL3529214 0.84 DGAT1 (0.34) BPGMALDH1A1MDM2CASP3
SCHEMBL3527487 0.83 TRPM8 (0.39) BPGMALDH1A1TRPM8PLA2G2APLA2G10
SCHEMBL3526099 0.82 BPGM (0.33) BPGMALDH1A1PLA2G2APLA2G10PLA2G1B
SCHEMBL3530133 0.82 PRKDC (0.39) BPGMALDH1A1TRPM8MDM2
SCHEMBL3744980 0.82 ALDH1A1 (0.38) BPGMALDH1A1PLA2G2APLA2G10PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1931337-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG BPGM 1563/4885ALDH1A1 600/4885TRPM8 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.